Haridus- ja Teadusministeerium
Maaeluministeerium
Sotsiaalministeerium
Rektorite Nõukogu 14.02.2020 nr 8-4/20/716
Küsimustik uute geenitehnoloogia meetodite kohta
Euroopa Komisjon viib liikmesriikides läbi uuringut lähtudes Euroopa Nõukogu 8. novembri 2019 otsusest
(EL) 2019/1904, millega palutakse komisjonil esitada Euroopa Kohtu poolt kohtuasjas C-528/16 tehtud
otsuse alusel uuring, mis käsitleb uute geenitehnoloogiate staatust liidu õiguse raames, ja ettepanek, kui see
on uuringu tulemustest lähtuvalt asjakohane.
2016. a küsis Prantsusmaa Euroopa Liidu (EL) Kohtu seisukohta uute mutageneesi meetodite staatuse
kohta. EL Kohus otsustas 25. juulil 2018 (kohtuasi C-528/16), et organismid, mis on saadud uute, suunatud
mutageneesi meetoditega, kuuluvad geneetiliselt muundatud organismide (GMO) hulka. Järelikult
kuuluvad ELis selle tehnoloogia abil toodetud organismid ja saadused edaspidi GMOsid reguleerivate
õigusaktide alla ning peavad läbima GMOde turule lubamise menetluse ja kuuluvad märgistamisele kui
GM tooted.
Otsusega kaasnes õigusselgus uute mutageneesi meetodite staatuses, kuid ilmnesid praktilised küsimused,
millel on tagajärjed riikide pädevatele asutustele, liidu tööstusele, eriti sordiaretussektoris, teadusuuringutes
ja mujalgi. Need küsimused käsitlevad muu hulgas seda, kuidas tagada direktiivi 2001/18/EÜ järgimine,
kui uute mutageneesi meetodite abil saadud tooteid ei saa praeguste meetoditega eristada toodetest, mis on
loomulikul teel muteerunud, ja kuidas sellises olukorras tagada importtoodete ning liidus valminud toodete
võrdne kohtlemine.
Olukorra selgitamiseks palus Euroopa Nõukogu teha Euroopa Komisjonil uuringu ning ühe osana uuringust
koostas komisjon liikmesriikidele suunatud küsitluse uute geenitehnoloogia meetodite kohta.
Keskkonnaministeerium tegeleb küsitluse vastuste koondamisega ning sellega seoses palume teilt sisendit
vastavalt teie valdkonnale hiljemalt 20. märtsiks. Palume teil võimalusel vastuseid koostades konsulteerida
ka oma haldusala pädevate üksustega. Juhime tähelepanu, et liikmesriikide vastused avaldatakse
Euroopa Komisjoni kodulehel.
Täiendavate küsimuste puhul palume pöörduda looduskaitse osakonna peaspetsialist Teele Jairuse
(
[email protected]) poole.
Lugupidamisega
(allkirjastatud digitaalselt)
Meelis Münt
Kantsler
Lisa: Küsimustik
Teele Jairus, 626 2886
[email protected]
Narva maantee 7a/ Tallinn 15172/ 626 2802/
[email protected]/ www.envir.ee/
Registrikood 70001231
Questionnaire on new genomic techniques to contribute to the study
requested by the Council
endorsed in the Joint Working Group of GMO competent authorities on new genomic
techniques
on 15 January 2020
Introduction
With this questionnaire the Commission is collecting contributions from Member States
competent authorities to respond to the Council’s request1 for a study on the status of new
genomic techniques. The scope of the study goes beyond new mutagenesis techniques, as
there are other new techniques, for which the Council seeks clarification. Therefore, the
study covers all new genomic techniques, which have been developed after 2001.
For the purpose of the study, the following definition for new genomic techniques (NGTs) is
used: techniques, which are capable to alter the genetic material of an organism and which
have emerged or have been developed since 20012.
Unless specified otherwise, the term “NGT-products” used in the questionnaire covers
plants, animals, micro-organims and derived food and feed products obtained by NGTs for
agri-food, medicinal and industrial applications and for research. GMO competent
authorities are invited to seek input from other competent authorites when appropriate.
The questionnaire is meant to provide information primarly, but not exclusively, at national
level. Please substantiate your replies with explanations, data and source of information as
well as with practical examples, whenever possible. If a reply to a specific question only
applies to a specific NGT, please indicate this in the reply. With regard to agri-food
applications, replies may include considerations on specific sectors, such as the organic
sector.
Please indicate which information should be treated as confidential in order to protect the
commercial interests of a natural or legal person.
Member States have until 15 April 2020 (close of business) to submit the questionnaire via
EUsurvey.
1
Council Decision (EU) 2019/1904
2
Examples of techniques include: 1) Genome editing techniques such as CRISPR, TALEN, Zinc-finger nucleases,
mega nucleases techniques, prime editing etc. These techniques can lead to mutagenesis and some of them
also to cisgenesis, intragenesis or transgenesis. 2) Mutagenesis techniques such as oligonucleotide directed
mutagenesis (ODM). 3) Epigenetic techniques such RdDM. Conversely, techniques already in use prior to
2001, such as Agrobacterium mediated techniques or gene gun, are not considered NGTs.
1
Questionnaire
Implementation and enforcement of the GMO legislation with regard to new genomic
techniques:
1. Have you been consulted by companies/organisations/research institutes for
regulatory advice or another issue on products developed or to be developed by
NGTs ? Yes/no
o If yes, please provide details on the request.
2. Have you taken specific measures (other than inspection) related to the application
of the GMO legislation to NGT-products? Yes/no
o If yes, please describe the measures and, if possible, their effectiveness.
o If yes, what best practices can you share?
o If no, please explain why not.
o If yes or no, have you encountered any challenges or limitations, including
administrative burden or costs? Yes/no
If yes, please describe.
If yes, how could this challenges or limitations be overcome?
If no, please expain why not.
3. Have you adapted your inspection practices to cover all NGT-products and to ensure
the enforcement of traceability requirements? Yes/no
o If yes, please describe these practices (e.g. adaptation of multiannual control
plans) and, if possible, their effectiveness (including of physical checks).
o If yes, what best practices can you share?
o If yes, have the adapted inspection practices created additional
requirements/burden for operators and/or public authorities? Yes/no
If yes, please provide concrete examples/data.
o If no, please explain why not.
o If yes or no, have you encountered challenges or limitations, including
administrative burden or costs? Yes/no
If yes, please describe.
If yes, how could these challenges or limitations be overcome?
If no, please explain why not.
4. Do you have experience or information on traceability strategies, which could be
used for tracing NGT-products? Yes/no
o If yes, please describe the traceability strategy, including details on the
required financial, human resources and technical expertise required.
o If yes, what best practices can you share?
o If yes or no, have you encountered challenges or limitations, including
administrative burden or costs? Yes/no
If yes, please describe.
If yes, how could these challenges or limitations be overcome?
2
If no, please explain why not.
5. What other experience can you share on the application of the GMO legislation,
including experimental releases (such as field trials and clinical trials), concerning
NGT-products in
o agri-food sector;
o industrial sector;
o medicinal sector.
6. Have plant varieties obtained by NGTs been registered in national catalogues? Yes/no
o If yes, please specify.
7. Do you require specific information in national catalogue when registering plant
varieties obtained by NGTs? Yes/no
o If yes, please specify.
Information on research and innovation:
8. Have you supported with national funding programmes NGT-related research
projects/programs (ongoing or finalised in the last 5 years), including on
identification or traceability? Yes/no
o If yes, please provide an overview of the project/program including title of
project, a brief summary with scope and objectives, the amount of national
funding received and possibly specify if the receiving entity is public or
private.
o If yes or no, please highlight the potential challenges encountered when
supporting/funding NGT-related research and any consequences from these
challenges.
9. How do you see NGT-related research evolving?
10. Have you identified any NGT-related research needs from private or public entities?
Yes/no
o If yes, please specify which needs and how they could be addressed.
11. Could NGT-related research bring opportunities/benefits to science, to society and to
the agri-food, medicinal or industrial sector? Yes/no
o If yes, please provide concrete examples/data.
o If no, please explain why not.
12. Could NGT-related research bring challenges/concerns to science, to society and to
the agri-food, medicinal or industrial sector? Yes/no
o If yes, please provide concrete examples/data.
o If no, please explain why not.
Information on public dialogues and national surveys:
13. Have you or other institutions/bodies/entities organised national dialogues
concerning NGTs? Yes/no
3
o If yes, please describe briefly the content, methodology and conclusions.
14. Have you or other institutions/bodies/entities organised national surveys, which
assessed public opinion on NGTs? Yes/no
o If yes, please describe briefly the content, methodology and conclusions.
Information on ethical aspects:
15. Have any national bodies or expert groups discussed or issued opinion on the ethical
aspects of NGTs? Yes/no
o If yes, please describe briefly the content, methodology and conclusions.
Information on potential opportunities and benefits from the use of NGTs and NGT-products:
16. Could the use of NGTs and NGT-products bring opportunities/benefits to the agri-
food, medicinal or industrial sector? Yes/no
o If yes, please provide concrete examples/data.
o If no, please explain why not.
17. Could the use of NGTs and NGT-products bring opportunities/benefits to society in
general, such as for the environment, human, animal and plant health, as well as
social and economic benefits, in the short, medium and long term? Yes/no
o If yes, please provide concrete examples/data.
o If no, please explain why not.
18. Do you see particular opportunities for SMEs on the market access to NGTs? Yes/no
o If yes, please explain under which conditions
o If no, please explain why not.
19. Do you see benefits/opportunities in patenting or accessing patented NGTs or NGT-
products? Yes/no
o If yes, please describe and provide concrete examples/data .
o If no, please explain why not.
Information on potential challenges and concerns of NGT products:
20. Could the use of NGTs and NGT-products raise challenges/concerns for the agri-food,
medicinal or industrial sector? Yes/no
o If yes, please provide concrete examples/data.
o If no, please explain why not.
21. Could the use of NGTs and NGT-products raise challenges/concerns for society in
general, such as for the environment, human, animal and plant health, as well as
social and economic challenges, in the short, medium and long term? Yes/no
o If yes, please provide concrete examples/data.
o If no, please explain why not.
22. Do you see particular challenges for SMEs on market access to NGTs? Yes/no
o If yes, please explain under which conditions.
o If no, please explain why not.
4
23. Do you see challenges/concerns in patenting or accessing patented NGTs or NGT-
products? Yes/no
o If yes, please describe and provide concrete examples/data.
o If no, please explain why.
Final question
24. Do you have other comments you would like to make? Yes/no
o If yes, please provide your comments here.
5